Figure 1.

FLD exerts effects on lipid homeostasis, in vivo and in vitro, that are distinct from those of full-length Angptl4. A, graphical depiction of the Ad-ANGPTL4 and Ad-FLD constructs. B, top panel, schematic showing adenoviral strategy to generate Ad-ANGPTL4, Ad-FLD, and Ad-LacZ mice. Bottom panel, immunoblot using anti-FLAG M2 antibody (Sigma, 1:1000) and a corresponding ANTI-FLAG affinity gel showing increased FLD abundance in the plasma of both Ad-ANGPTL4 and Ad-FLD mice (blot was cropped). C and D, plasma TG (C) and (D) FFA measurements showing that Ad-ANGPTL4 mice fed a standard chow diet have increased levels of both TG and FFAs versus Ad-LacZ controls, whereas Ad-FLD mice have elevated FFA levels without concomitant hypertriglyceridemia (n = 5–6 mice/group for A–D; *, p < 0.05 versus Ad-LacZ). E and F, glycerol release (E) and intracellular cAMP (F) levels measured from primary mouse adipocytes treated for 1 h with purified ANGPTL4, FLD, or the E40K mutant form of ANGPTL4 showing that each stimulates adipocyte lipolysis with similar potency (n = 7 mice/group; *, p < 0.05 versus PBS-treated controls).